Protelica is the exclusive owner of the intellectual property covering the Pronectin™ platform, including , the universal library of Pronectin™ (25 Billion protein variants), the unique process to produce its library and specific protein sequences isolated from the Library for specific targets. As Protelica conducts its drug discovery, individual therapeutic Pronectin™ programs will give rise to more specific composition of matter product and field of use protection, providing another layer of protection and an extended period of exclusivity for Pronectin-based therapeutics.
In addition to the above, Protelica’s technology and drug discovery platform include intellectual property related to DNA Mutagenesis, including but not limited to Walk-Through and Look-Through Mutagenesis, affinity maturation and immunoglobulin engineering and optimization. Protelica’s portfolio consists of more than seventy patent and patent applications as of May 2017, including key patents granted in the United States, Europe and Asia.
Issued US Patents include the following: US 9,376,483 Universal fibronectin type III binding domain libraries US 9,012,369 Look-through mutagenesis for developing altered polypeptides with enhanced properties US 8,716,195 Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening US 8,697,608 Universal fibronectin type III binding domain libraries US 8.680,019 Universal fibronectin type III binding domain libraries US 8,470,966 Universal fibronectin type III binding domain libraries US 6,649,340 Walk-through mutagenesis US 6,432,675 Combinatorial polypeptide antigens US 5,830,650 Walk-through mutagenesis US 5,798,208 Walk-through mutagenesis